Fatema Nader

5.7k total citations · 1 hit paper
76 papers, 3.9k citations indexed

About

Fatema Nader is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Fatema Nader has authored 76 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 59 papers in Hepatology and 8 papers in Surgery. Recurrent topics in Fatema Nader's work include Liver Disease Diagnosis and Treatment (62 papers), Hepatitis C virus research (37 papers) and Liver Disease and Transplantation (26 papers). Fatema Nader is often cited by papers focused on Liver Disease Diagnosis and Treatment (62 papers), Hepatitis C virus research (37 papers) and Liver Disease and Transplantation (26 papers). Fatema Nader collaborates with scholars based in United States, United Kingdom and France. Fatema Nader's co-authors include Zobair M. Younossi, Maria Stepanova, Arian Afendy, Manirath Srishord, Leah Burns, James M. Paik, Pegah Golabi, Leyla de Avila, Ying Qiu and Natsu Fukui and has published in prestigious journals such as Gastroenterology, Hepatology and Diabetes Care.

In The Last Decade

Fatema Nader

74 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

2019 1.5k citations Zobair M. Younossi, Pegah Golabi et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fatema Nader United States	29	3.4k	2.2k	1.3k	456	383	76	3.9k
Manirath Srishord United States	13	3.6k 1.1×	1.6k 0.7×	1.8k 1.4×	606 1.3×	668 1.7×	28	4.0k
Sanjaya K. Satapathy United States	31	2.5k 0.7×	1.7k 0.8×	674 0.5×	825 1.8×	445 1.2×	170	3.7k
Phunchai Charatcharoenwitthaya Thailand	26	4.9k 1.4×	2.9k 1.3×	1.9k 1.5×	1.3k 2.8×	695 1.8×	123	5.7k
Leyla de Avila United States	16	2.0k 0.6×	864 0.4×	1.0k 0.8×	381 0.8×	330 0.9×	36	2.5k
Alita Mishra United States	25	2.6k 0.8×	1.7k 0.8×	790 0.6×	523 1.1×	451 1.2×	42	3.1k
Matilde Marcellini Italy	27	2.3k 0.7×	1.2k 0.5×	1.0k 0.8×	622 1.4×	130 0.3×	62	3.1k
Richard T. Stravitz United States	21	2.2k 0.7×	1.6k 0.7×	772 0.6×	717 1.6×	311 0.8×	36	2.8k
Marcin Krawczyk Germany	33	1.8k 0.5×	898 0.4×	603 0.5×	1.1k 2.3×	271 0.7×	203	3.3k
Marcelo Kugelmas United States	18	1.8k 0.5×	1.5k 0.7×	441 0.3×	587 1.3×	343 0.9×	47	2.6k
Andrei Racila United States	20	2.1k 0.6×	1.3k 0.6×	734 0.6×	367 0.8×	300 0.8×	55	2.4k

Countries citing papers authored by Fatema Nader

Since Specialization

Citations

This map shows the geographic impact of Fatema Nader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatema Nader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatema Nader more than expected).

Fields of papers citing papers by Fatema Nader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatema Nader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatema Nader. The network helps show where Fatema Nader may publish in the future.

Co-authorship network of co-authors of Fatema Nader

This figure shows the co-authorship network connecting the top 25 collaborators of Fatema Nader. A scholar is included among the top collaborators of Fatema Nader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatema Nader. Fatema Nader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Younossi, Zobair M., et al.. (2025). Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments. Gastro Hep Advances. 4(6). 100642–100642.

Younossi, Zobair M., Sean Felix, Brian Lam, et al.. (2025). Serum Bile Acid Elevation is an Independently Associated With Pruritus in Patients With At-risk Metabolic Dysfunction-associated Steatotic Liver Disease. Journal of Clinical and Experimental Hepatology. 15(4). 102549–102549. 1 indexed citations

Younossi, Zobair M., James M. Paik, Linda Henry, et al.. (2025). Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK). Annals of Hepatology. 30(2). 101789–101789. 8 indexed citations

Younossi, Zobair M., Giacomo Germani, Robert Wong, et al.. (2025). Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: Trends and outcomes in the past 2 decades. Liver Transplantation. 32(4). 549–557. 1 indexed citations

Younossi, Z.M., Leyla de Avila, Andrei Racila, et al.. (2025). Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology. 82(5). 1229–1240. 5 indexed citations

Younossi, Zobair M., Andrei Racila, Linda Henry, et al.. (2024). Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis. Hepatology. 81(4). 1318–1327. 17 indexed citations

Alqahtani, Saleh A., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2024). Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region. Annals of Hepatology. 30(1). 101569–101569. 6 indexed citations

Alqahtani, Saleh A., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2024). Clinical and patient‐reported outcomes in patients with chronic hepatitis B and C and non‐alcoholic fatty liver disease from real‐world practices in Saudi Arabia, Turkey and Egypt. Journal of Viral Hepatitis. 31(6). 300–308. 4 indexed citations

Younossi, Zobair M., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2022). The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. Hepatology Communications. 6(10). 2860–2866. 3 indexed citations

10.

Younossi, Zobair M., Naim Alkhouri, Fasiha Kanwal, et al.. (2022). A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 57(3). 304–312. 22 indexed citations

11.

Younossi, Zobair M., James M. Paik, Pegah Golabi, et al.. (2022). The impact of fatigue on mortality of patients with non‐alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018. Liver International. 42(12). 2646–2661. 23 indexed citations

12.

Younossi, Zobair M., James M. Paik, Linda Henry, et al.. (2022). The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States. Journal of Clinical and Experimental Hepatology. 13(3). 454–467. 44 indexed citations

13.

Younossi, Zobair M., Maria Stepanova, Fatema Nader, et al.. (2021). Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clinical Gastroenterology and Hepatology. 20(9). 2050–2058.e12. 77 indexed citations

14.

Younossi, Zobair M., Sean Felix, Thomas L. Jeffers, et al.. (2021). Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology. 20(5). e1149–e1156. 3 indexed citations

15.

Younossi, Zobair M., Andrei Racila, Andrew J. Muir, et al.. (2021). Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clinical Gastroenterology and Hepatology. 20(2). 438–446. 10 indexed citations

16.

Younossi, Zobair M., Pegah Golabi, Leyla de Avila, et al.. (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 71(4). 793–801. 1517 indexed citations breakdown →

17.

Younossi, Zobair M., Radhika P. Tampi, Fatema Nader, et al.. (2019). Hypothetical treatment of patients with non‐alcoholic steatohepatitis: Potential impact on important clinical outcomes. Liver International. 40(2). 308–318. 4 indexed citations

18.

Younossi, Zobair M., Radhika P. Tampi, Andrei Racila, et al.. (2019). Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. Diabetes Care. 43(2). 283–289. 129 indexed citations

19.

Younossi, Zobair M., Maria Stepanova, Linda Henry, et al.. (2016). Association of work productivity with clinical and patient‐reported factors in patients infected with hepatitis C virus. Journal of Viral Hepatitis. 23(8). 623–630. 30 indexed citations

20.

Younossi, Zobair M., Maria Stepanova, Fatema Nader, Brian Lam, & Sharon Hunt. (2015). The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life. Alimentary Pharmacology & Therapeutics. 42(3). 286–295. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact